Novanta Inc is a scientific & technical instruments business based in the US. Novanta shares (NOVT) are listed on the NASDAQ and all prices are listed in US Dollars. Novanta employs 2,700 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $121.27 |
|---|---|
| 52-week range | $110.84 - $184.44 |
| 50-day moving average | $123.75 |
| 200-day moving average | $145.93 |
| Wall St. target price | $142.67 |
| PE ratio | 76.6139 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.58 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $121.27 from 2022-06-30
| 1 week (2022-06-21) | 5.55% |
|---|---|
| 1 month (2022-06-01) | -0.08% |
| 3 months (2022-03-29) | N/A |
| 6 months (2021-12-31) | -31.23% |
| 1 year (2021-07-02) | -11.72% |
|---|---|
| 2 years (2020-07-02) | 13.44% |
| 3 years (2019-07-02) | 31.67% |
| 5 years (2017-06-30) | 236.86% |
Valuing Novanta stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novanta's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novanta's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 77x. In other words, Novanta shares trade at around 77x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novanta's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novanta's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novanta's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $143.1 million.
The EBITDA is a measure of a Novanta's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $748.4 million |
|---|---|
| Operating margin TTM | 12.76% |
| Gross profit TTM | $305 million |
| Return on assets TTM | 5.8% |
| Return on equity TTM | 11.44% |
| Profit margin | 7.73% |
| Book value | $14.98 |
| Market capitalisation | $4.3 billion |
TTM: trailing 12 months
We're not expecting Novanta to pay a dividend over the next 12 months.
Novanta's shares were split on a 1:3 basis on 28 December 2010. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novanta shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Novanta shares which in turn could have impacted Novanta's share price.
Over the last 12 months, Novanta's shares have ranged in value from as little as $110.84 up to $184.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novanta's is 1.1089. This would suggest that Novanta's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Novanta Inc. , together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. It's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. In addition, its Precision Motion segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.